Neuronetics, Inc. (STIM)

Over 5 million New York Medicaid members to gain access to Transcranial Magnetic Stimulation (TMS) services Over 5 million New York Medicaid members to gain access to Transcranial Magnetic Stimulation (TMS) services

MALVERN, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to six new employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient's continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company's 2020 Inducement Incentive Plan.

Neuronetics, Inc. (NASDAQ:STIM ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Keith J. Sullivan - President, CEO & Director Steven E.

Neuronetics (STIM) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.33 per share a year ago.

MALVERN, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that Keith Sullivan, President and Chief Executive Officer, will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025. The Company is scheduled to present at 1:30pm Eastern Time the same day. The presentation will be available via the conference portal to registered attendees and presenting companies for 14 days following the event. About Neuronetics Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (Greenbrook) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of MDD and other mental health disorders. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults, with more than 7.4 million treatments delivered, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world's largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1 Greenbrook has provided more than 1.8 million treatments to over 55,000 patients struggling with depression. The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com. Investor Contact: Mike Vallie or Mark KlausnerICR Healthcare443-213-0499 ir@neuronetics.com Media Contact: EvolveMKD646-517-4220 NeuroStar@evolvemkd.com

Real-world data showing NeuroStar is effective in adolescents and young adults with depression from the world's largest TMS outcomes dataset Real-world data showing NeuroStar is effective in adolescents and young adults with depression from the world's largest TMS outcomes dataset

Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Steve Furlong as Chief Financial Officer following previously announced succession process

MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to one new non-executive employee as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient's continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company's 2020 Inducement Incentive Plan.

NeuroStar, a Silver Sponsor at CTMSS, will also present two posters as part of the Company's ongoing commitment to clinical innovation and excellence NeuroStar, a Silver Sponsor at CTMSS, will also present two posters as part of the Company's ongoing commitment to clinical innovation and excellence

MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) --  Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that it is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US market opens on June 30, 2025.

Neuronetics, Inc. (NASDAQ:STIM ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President & Chief Executive Officer Steve Furlong - Chief Financial Officer Conference Call Participants Margaret Kaczor Andrew - William Blair William Plovanic - Canaccord Genuity Adam Maeder - Piper Sandler Danny Stauder - Citizens JMP Operator Good day, and thank you for standing by. Welcome to the Neuronetics First Quarter 2025 Financial and Operating Results Conference Call.

Neuronetics (STIM) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.27 per share a year ago.

MALVERN, Pa., May 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2025.

MALVERN, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 4,500 shares of the Company's common stock (RSUs) to three new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as material inducements to their respective employment with the Company.

Policy update increases access for millions covered by Evernorth Health Services Policy update increases access for millions covered by Evernorth Health Services

Neuronetics has shown significant growth, with a 430% rally since November and strong Q4 2024 results, driven by its NeuroStar TMS therapy system. The company's valuation remains attractive despite recent gains, with a forward P/S ratio of 1.71x, well below sector norms, indicating potential undervaluation. Strategic acquisitions, including Greenbrook, and FDA approvals are expected to drive revenue growth and cash flow positivity by Q3 2025.